Miguel Ángel C.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase 3 Randomized Study of Perioperative Enfortumab Vedotin and Pembrolizumab Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
- Phase II Randomized Trial of Neo-adjuvant vs. Adjuvant Cisplatin-Based Chemotherapy in Upper Tract Urothelial Carcinoma with Gemcitabine
- A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
Data & Insights
Has run more than one trial at 23 of 120 partner sites.
Specializations
Prostate Cancer Research
Specializes in investigating novel therapeutic approaches for metastatic prostate cancer, with particular focus on hormone-naïve and castration-resistant variants.
- Advanced hormonal therapies
- PSMA-targeted treatments
- Combination therapy approaches
Investigates innovative treatment combinations including enzalutamide, talazoparib, and abiraterone acetate for prostate cancer management.
Bladder Cancer Studies
Focuses on advancing treatment options for muscle-invasive bladder cancer and metastatic urothelial carcinoma.
- Immunotherapy combinations
- Perioperative treatments
- Trimodality therapy approaches
Explores novel therapeutic combinations including immunotherapy agents and targeted treatments for bladder cancer patients.
Renal Cell Carcinoma Expertise
Conducts research in advanced renal cell carcinoma, including both clear cell and non-clear cell variants.
- Targeted therapy combinations
- Immunotherapy approaches
- Novel therapeutic strategies
Evaluates innovative treatment combinations including checkpoint inhibitors and targeted therapies for kidney cancer treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.